Jounce Therapeutics Inc (JNCE) Gets a Hold Rating from Cowen & Co.


In a report released today, Boris Peaker from Cowen & Co. maintained a Hold rating on Jounce Therapeutics Inc (JNCE). The company’s shares opened today at $5.22, close to its 52-week low of $2.66.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.4% and a 41.3% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Molecular Templates Inc.

Jounce Therapeutics Inc has an analyst consensus of Hold, with a price target consensus of $13.

See today’s analyst top recommended stocks >>

The company has a one-year high of $19.16 and a one-year low of $2.66. Currently, Jounce Therapeutics Inc has an average volume of 211.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts